Evidence map›Paper›PMID 37482614›Full record

ArticleJournal of translational medicine2023

Time- and cost-effective production of untagged recombinant MVA by flow virometry and direct virus sorting.

Daniela Boselli, Maddalena Panigada, Simona Di Terlizzi, Monica Romanò, Emanuele Canonico, Chiara Villa, Claudia Minici, Eelco van Anken, Elisa Soprana, Antonio G Siccardi

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Journal of translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Daniela Boselli *FRACTAL - San Raffaele Scientific Institute, Milan, Italy.
Maddalena Panigada *Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milan, Italy.
Simona Di TerlizziFRACTAL - San Raffaele Scientific Institute, Milan, Italy.
Monica RomanòFRACTAL - San Raffaele Scientific Institute, Milan, Italy.
Emanuele CanonicoFRACTAL - San Raffaele Scientific Institute, Milan, Italy.
Chiara VillaFRACTAL - San Raffaele Scientific Institute, Milan, Italy.
Claudia MiniciDivision of Genetics and Cell Biology, San Raffaele Scientific Institute, Milan, Italy.
Eelco van AnkenUniversità Vita-Salute San Raffaele, Milan, Italy.
Elisa SopranaDivision of Genetics and Cell Biology, San Raffaele Scientific Institute, Milan, Italy.
Antonio G SiccardiDivision of Genetics and Cell Biology, San Raffaele Scientific Institute, Milan, Italy. antoniosiccardi@me.com.ORCID http://orcid.org/0000-0002-1654-5545
San Raffaele University of Rome · ITVita-Salute San Raffaele University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecombinant MVAs (rMVAs) are widely used both in basic and clinical research. Our previously developed Red-to-Green Gene Swapping Method (RGGSM), a cytometry-based Cell-Sorting protocol, revolves around the transient expression of a green fluorescent cytoplasmic marker, to subsequently obtain purified untagged rMVA upon loss of that marker by site-specific recombination. The standard RGSSM is quite costly in terms of bench work, reagents, and Sorting Facility fees. Although faster than other methods to obtain recombinant MVAs, the standard RGSSM still is time-consuming, taking at least 25 days to yield the final product.

methodsThe direct sorting of fluorescent virions is made amenable by the marker HAG, a flu hemagglutinin/EGFP fusion protein, integrated into the external envelope of extracellular enveloped virions (EEVs). Fluorescent EEVs-containing supernatants of infected cultures are used instead of purified virus. Direct Virus-Sorting was performed on BD FACSAria Fusion cell sorter equipped with 4 lasers and a 100-mm nozzle, with 20 psi pressure and a minimal flow rate, validated using Megamix beads.

resultsUpon infection of cells with recombinant EEVs, at the first sorting step virions that contain HAG are harvested and cloned, while the second sorting step yields EEVs that have lost HAG, allowing to clone untagged rMVA. Because only virion-containing supernatants are used, no virus purification steps and fewer sortings are necessary. Therefore, the final untagged rMVA product can be obtained in a mere 8 days.

conclusionsAltogether, we report that the original RGSSM has been markedly improved in terms of time- and cost efficiency by substituting Cell-Sorting with direct Virus-Sorting from the supernatants of infected cells. The improved virometry-based RGGSM may find wide applicability, considering that rMVAs hold great promise to serve as personalized vaccines for therapeutic intervention against cancer and various types of infectious diseases.

Indexed as

Vaccinia virusVirionCost-Benefit AnalysisEEV and IMV virionsFlow VirometryHemagglutinin/egfp fusion proteinRecombinant MVARed-to-Green Gene Swapping MethodrMVAVirus-Sorting

Identifiers

PMID37482614
PMCPMC10364397
OpenAlexW4385175543

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.